CADL Jan 2025 8.000 call
| Previous Close | 2.9000 |
| Open | 3.0000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 8.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 2.9000 - 3.1000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 202 |
ACCESSWIRECandel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
By Jeremy Golden, Benzinga NEEDHAM, MA / ACCESSWIRE / June 3, 2024 / Clinical-stage biopharmaceutical company Candel Therapeutics, Inc. (NASDAQ:CADL) reported updated survival data from its randomized phase 2 clinical trial of CAN-2409 in borderline ...
GlobeNewswireFDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
FDA Orphan Designation provides CAN-3110 certain developmental financial incentives, with potential for up to 7 years of marketing exclusivity in the United States, if approvedCAN-3110 phase 1b data on the feasibility and safety of multiple doses of CAN-3110 will be featured in poster presentation at 2024 ASCO Annual Meeting NEEDHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on deve
ZacksCandel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications.
